MIM
JBIO

MetLife Investment Management’s Jade Biosciences JBIO Stock Holding History

MetLife Investment Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Sell
17,935
-8,134
-31% -$118K ﹤0.01% 2108
2025
Q4 		$402K Buy
26,069
+12,785
+96% +$150K ﹤0.01% 1894
2025
Q3 		$115K Buy
+13,284
New +$109K ﹤0.01% 2592
2024
Q2 		– Sell
-149
Closed -$98.8K – 2885
2024
Q1 		$155K Hold
149
– – ﹤0.01% 2332
2023
Q4 		$118K Hold
149
– – ﹤0.01% 2523
2023
Q3 		$70.9K Hold
149
– – ﹤0.01% 2758
2023
Q2 		$89.7K Hold
149
– – ﹤0.01% 2742
2023
Q1 		$105K Hold
149
– – ﹤0.01% 2527
2022
Q4 		$153K Buy
+149
New +$108K ﹤0.01% 2408

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MetLife Investment Management's JBIO Position: Q1 2026 in Review

MetLife Investment Management reduced its Jade Biosciences (JBIO) stake by 31% in Q1 2026, selling an estimated $118K and leaving 17,935 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2108.

MetLife Investment Management first reported a position in JBIO in Q4 2022 and has held it in 9 quarters since. The position peaked at $402K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • MetLife Investment Management held 17,935 shares of Jade Biosciences worth $252K as of Q1 2026.
  • MetLife Investment Management sold 8,134 Jade Biosciences shares in Q1 2026, an estimated $118K.
  • Jade Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2108 holding.
  • MetLife Investment Management first reported a position in Jade Biosciences in Q4 2022 and has held it in 9 quarters since.
  • MetLife Investment Management's Jade Biosciences position peaked at $402K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.